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The aim of our analysis was to assess retrospectively the effect on local relapse, overall survival (OS) and disease-free survival (DFS)
of a limited or an extended lymphadenectomy in radically resected gastric cancer patients. This study was performed in order to
identify a subgroup of patients possibly not benefiting from a therapeutic approach such as chemoradiation therapy. We divided our
patients into two groups according to lymphadenectomy type: group A for limited (o25 resected lymph nodes) and group B for
extended (425 resected lymph nodes) lymph nodes resection. A total of 418 patients were analysed: tumour stage at diagnosis was
pT2–3 pN1–3 M0 in 339 patients and pT3 N0 M0 in 79 patients. Median age at diagnosis was 68 years (range 30–92 years). A total
of 306 patients (73.2%) were in group A and 112 (26.8%) in group B. The median survival time (OS) for patients in groups A and B
was 58.8 and 84.8 months, respectively (P¼0.0371); median DFS was 28.8 months in group A and 59.9 months in group B
(P¼0.0027). At multivariate analysis, extension within the gastric wall, nodal involvement and the number of resected lymph nodes
appeared to affect both OS and DFS. An inadequate lymph nodes resection can affect survival and result in a higher incidence of local
relapse, making the latter group of patients optimal candidates for adjuvant chemoradiation.
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Although in the last few years the overall incidence of gastric
cancer has gradually decreased worldwide, it remains second only
to that of lung cancer, with an estimated 755000 new cases
diagnosed annually around the world (Jemal et al, 2002). Although
many advances have been made in the diagnosis and treatment of
gastric cancer, the global outcome for patients diagnosed with this
disease is still disappointing with a 5-year survival rate not
exceeding 30% of all cases in Western Countries (Bouvier et al,
2002; Nitti et al, 2003).
In operable gastric cancer, both the extent of surgery and the
value of adjuvant treatment remain matter of scientific debate,
with surgery still representing the cornerstone of any curative
procedure (van de Velde and Peeters, 2003; Hohenberger and
Gretschel, 2003). Nevertheless, controversy still exists about the
adequate extent of lymphadenectomy, which may be limited to
perigastric lymph nodes (D1 dissection) or may include removal of
the lymphatic chains along the celiac axis, the common hepatic
and splenic artery and the hilus of the spleen (D2 dissection) (Kim
and Karpeh, 2002; Alberts et al, 2003; Nitti et al, 2003).
Although a D2 dissection is the generally accepted surgical
procedure in Japan, the debate about the benefits of D1 vs D2
lymph nodes dissection is still ongoing (Bonenkamp et al, 1999;
Cuschieri et al, 1999; Davis and Sano, 2001; Lewis et al, 2002; Reis
et al, 2002; Sierra et al, 2003).
More recently, a general agreement has been achieved about a
so-called over-D1 lymphadenectomy (D1 dissection and retrieval
of at least 25 nodes) on the basis of the finding that the probability
of accurate assessment of lymph node status increases with the
number of nodes resected, with a plateau reached at 20–25 nodes
(Marubini et al, 2002).
Although this recommendation addresses to the principle that
lymph nodes are regarded as indicators rather than governors of
disease, several clinical data also indicated that a lymph nodes
resection including more than 25 lymph nodes could have a major
impact on the global outcome of patients who underwent apparent
radical surgery for gastric cancer (Siewert et al, 1998; Marubini
et al, 2002). It has been suggested that this improvement could be
mainly due to a reduction in local recurrences (Kim and Karpeh,
2002).
Furthermore, it has been recently reported that a chemo-
radiotherapy adjuvant approach may improve the outcome of
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sradically resected gastric cancer by lowering the incidence of local
relapse (Macdonald et al, 2001).
The aim of our analysis was to assess retrospectively the possible
effects on local relapse, and consequently on overall survival (OS)
and disease-free survival (DFS), of limited or extended lympha-
denectomy in a homogeneous group of radically resected gastric
cancer patients. This analysis was performed in order to identify a
subgroup of patients not likely to benefit from a toxic therapeutic
approach such as chemoradiation therapy.
PATIENTS AND METHODS
Patients selection
The study population was selected from a central database that
includes 765 patients with gastric cancer operated in four different
institutions.
At the end of each surgical resection, all nodes were dissected
from the specimen by a member of the surgical team. Classification
of the N-factor was made according to the numeric system
introduced by the fifth TNM (N1: metastases in 1–6 regional
lymph nodes; N2: metastases in 7–15 regional lymph nodes; N3:
metastases in more than 15 regional lymph nodes) (Sobin and
Wittekind, 1997).
A total of 418 patients were eligible for our analysis: 339 patients
with pT2–3 pN1–3 M0 (tumour invading muscolaris or serosa
(T2–3), lymph node metastasis in one to more than 15 regional
lymph nodes (N1–3), no distant metastasis (M0)) and 79 patients
with pT3 N0 M0.
Our analysis was limited to pT3N0, pT2–3Nþ tumours since
they either represent the largest group of patients candidates to
radical surgery and those in which an adjuvant therapy may have a
role in improving prognosis.
A dissection of o25 or more than 25 lymph nodes was,
respectively, classified as limited or extended lymphadenectomy. A
cutoff of 25 resected lymph nodes has been arbitrarily chosen
according to data reported by Marubini et al (2002), Siewert et al
(1998) and Wagner et al (1991). Therefore, we divided our patients
into two groups: group A for limited and group B for extended
lymph nodes resection. All surgical centres involved presented
comparable characteristics for the number of gastric cancer
patients seen and the number of surgical procedures performed
per year. All surgeons involved had the same scientific background
and training.
Follow-up of both groups occurred at 3 months intervals for 2
years, then at 6 months intervals for 3 years and yearly thereafter.
Follow-up consisted of physical examination, a complete blood
count, chest radiography and CT scanning as clinically indicated.
The site and date of first relapse and the date of death were
recorded.
Data management and statistical analysis
Statistical analysis was performed with SAS software version 8.2
for Windows (SAS Institute Inc., Cary, NC, USA).
The association between categorical variables was estimated by
w
2 test.
Survival distribution was estimated by the Kaplan–Meier
method (Kaplan and Meier, 1958). Significant differences in
probability of relapsing between the strata were evaluated by
log-rank test.
Cox multiple regression analysis was used to assess the role of
lymphadenectomy as prognostic factor adjusted for those variables
significant at univariate analysis (Cox, 1972).
Hazard ratios and 95% confidence intervals were estimated from
regression coefficients. A significant level of 0.05 was chosen to
assess the statistical significance.
For statistical analysis, OS and DFS were defined, respectively, as
the interval between radical surgery and death or last follow-up
visit and as the interval between radical surgery and clinical
progression or death or last follow-up visit if not progressed.
RESULTS
A total of 418 patients were eligible for our analysis: 339 patients
with pT2–3 pN1–3 M0 and 79 patients with pT3 N0 M0. A total of
249 patients were males (59.6%) and 169 females (40.4%), and
median age at diagnosis was 68 years (range 30–92). A total
gastrectomy was performed in 249 patients (59.6%), whereas the
remaining patients underwent a subtotal resection of the stomach.
A total of 306 patients (73.2%) received a limited and 112
(26.8%) an extended lymph nodes dissection. In all, 210 patients
(50.2%) were classified as N1, 98 (23.5%) as N2, 31 (7.4%) as N3
and 79 (18.9%) as N0. In the whole group, a median of 18 (range
0–68) lymph nodes were resected. A total of 66 patients (15.8%)
had a pT2 and 352 (84.2%) had a pT3 gastric cancer (Table 1).
With a median follow-up of 25 months (range 1–130 months), we
recorded information on the site of the first relapse and these sites
were categorised as local or distant (Table 2). Local recurrence
occurred in 23% of cases with o25 lymph nodes resected and in
4.7% of those with 425 lymph nodes resected (P¼0.0001); however,
37% of those with o25 lymph nodes resected and 24.8% of those
with 425 lymph nodes resected had distant relapses (P¼0.12).
The median DFS for patients in groups A and B was,
respectively, 28.8 and 59.9 months (P¼0.0027) (Figure 1). At
multivariate analysis, extended lymph node dissection appeared an
independent prognostic factor for DFS (HR¼0.52, CI 0.36–0.74,
P¼0.0003), which was also influenced by extension within the
gastric wall (pT2 vs pT3; HR¼0.41, CI 0.26–0.63, P¼0.0001) and
nodal involvement (N0 vs Nþ;H R ¼0.33, CI 0.21–0.52,
P¼0.0001).
The extension of lymphadenectomy also resulted determinant in
median survival time (OS) with an OS of 58.8 months for patients
Table 1 Patients characteristics
Whole group Group A (%) Group B (%)
Number 418 306 (73.2) 112 (26.7)
Age (range) 68 (30–92) 68 (30–92) 67 (33–87)
Sex
Male 249 189 (61.8) 60 (53.6)
Female 169 117 (38.2) 52 (46.4)
Gastrectomy
Total 249 155 (50.7) 94 (84)
Subtotal 168 151 (49.3) 18 (16)
pT stage
pT2 66 53 (17.3) 13 (11.6)
pT3 352 253 (82.7) 99 (88.4)
pN stage
pN0 79 59 (19.3) 20 (17.9)
pN1 210 165 (53.9) 45 (40.2)
pN2 98 73 (23.9) 25 (22.3)
pN3 31 9 (2.9) 22 (19.6)
Table 2 Local and distant relapse
Resected
lymph nodes Patients
Local
relapse (%)
Distant
relapse (%)
p25 306 71 (23%) 115 (37%)
425 112 5 (4.7%) 28 (24.8%)
P-value 0.0001 0.12
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sin group A and 84.8 months for patients in group B (P¼0.0371)
(Figure 2).
At multivariate analysis, three variables seemed to influence OS:
extension within the gastric wall (pT2 vs pT3; HR¼0.47, CI 0.29–
0.76, P¼0.002), nodal involvement (N0 vs Nþ;H R ¼0.46, CI
0.29–0.74, P¼0.0015) and the number of resected lymph nodes
(425 vs o25; HR¼0.59, CI 0.39–0.89, P¼0.012).
These results were confirmed in subgroups analysis, separately
considering N-positive and N-negative patients. In fact, among N-
positive patients, OS was 51.3 months for those who received
limited lymphadenectomy and 84.8 months for those who received
extended lymphadenectomy (P¼0.0316).
Also, DFS appeared to be influenced by the extension of
lymphadenectomy in this latter group of patients, as it was 22.4
months for patients who underwent limited lymphadenectomy and
56.6 months for patients who underwent extended lymphadenect-
omy (P¼0.0036).
In N-negative patients, DFS was progressively affected by a
progressively more extended lymph nodes dissection: at a follow-
up of 25 months (range 1–130 months), the DFS of patients with
0–6 and 7–15 resected lymph nodes was, respectively, 23 and 30
months, while it was not reached for patients with 16–22 and with
more than 22 resected lymph nodes. The difference between the
four survival curves was statistically significant (P¼0.0067)
(Figure 3). Similar results were observed for OS: for patients with
0–6 and 7–15 resected lymph nodes, OS was, respectively, 24 and
76 months, while OS was not reached for patients with 16–22 and
with more than 22 resected lymph nodes (P¼0.0032) (Figure 4).
DISCUSSION
One of the main reasons for disease progression in apparently
radically resected gastric cancer patients is represented by the
frequent occurrence of locoregional relapse (Macdonald et al,
2001; Gunderson, 2002; Park et al, 2003). This high incidence of
local relapse provided the rationale for the INT-0116 trial
(Macdonald et al, 2001). In fact, this trial showed that a
chemoradiotherapy adjuvant approach was able to improve
prognosis mainly by lowering the incidence of local relapse (from
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Figure 1 Disease-free survival of gastric cancer patients undergoing
limited (p25 lymph nodes resected, group A ----) or extended (425
lymph nodes resected, group B —) lymphadenectomy.
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Figure 2 Overall survival of gastric cancer patients undergoing limited
(p25 lymph nodes resected, group A ----) or extended (425 lymph
nodes resected, group B —) lymphadenectomy.
0 20 40 60 80 100 120 140
0
25
50
75
100
0–6 lymph nodes resected
7–15 lymph nodes resected
16–22 lymph nodes resected
>22 lymph nodes resected
 DFS (months)
P
a
t
i
e
n
t
s
 
(
%
)
P=0.0067
Figure 3 Disease-free survival in lymph nodes-negative gastric cancer
patients. Kaplan–Meier curves show that a progressively more extended
lymphadenectomy correlates with a progressively better DFS.
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Figure 4 Overall survival in lymph nodes-negative gastric cancer
patients. Kaplan–Meier curves show that a progressively more extended
lymphadenectomy correlates with a progressively better OS.
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metastatic diffusion.
The quality of surgical treatment in this latter study can be
considered inadequate, as a substantial proportion of patients
(54%) underwent a D0 resection (no clearance of the lymphatics).
On the basis of these considerations, the results of the INT-0116
trial could also be interpreted according to the hypothesis of
having treated residual disease by radiochemotherapy in a signi-
ficant subgroup of patients (Macdonald et al, 2001; Hohenberger
and Gretschel, 2003).
Our results seem to confirm these conclusions. In fact, patients
undergoing an optimal surgery experienced a local relapse rate as
low as 4.7%, whereas this was 21% in patients receiving a
suboptimal surgery. Another important aspect arising from our
analysis is once again the lack of effect of optimal surgery on
distant metastases. Similar findings were found in the INT-0116
study, when the effects of radiochemotherapy on distant metas-
tases were analysed.
The results we presented in our study seem to go along with data
from Siewert et al (1998) and Macdonald et al (2001) (also
Hundahl et al, 2002). In these two studies, a survival advantage was
suggested for extended lymphadenectomy and in our analysis, the
median survival time for patients in groups A and B was,
respectively, 58.8 and 84.8 months (P¼0.0371). An apparent
imbalance for the type of gastrectomy (i.e. total vs subtotal
gastrectomy in the two groups) could be noticed in our series. In
fact, about 84% of the patients in group A had a total gastrectomy
compared to 50.7% of those in the limited lymphadenectomy
group (group B). Therefore, it can be postulated that this latter
factor may have affected recurrence and survival. Nevertheless, it
has already been demonstrated that the extent of gastrectomy
(total or subtotal) has no impact on the global outcome of radically
resected gastric cancer patients (Bozzetti et al, 1997).
Although not demonstrated in our data analysis, which did not
directly address the role of adjuvant treatment in gastric cancer
patients, these findings seem to question the role of adjuvant
chemoradiotherapy as a standard of practice in all gastric cancer
patients, whereas its role could be that of a partially compensation
for an inadequate surgery.
The question remains whether novel and effective chemother-
apeutic agents could have a role along with optimal surgery, in
order to further improve survival in optimally resected gastric
cancer patients.
Therefore, we can hypothesise that patients undergoing
suboptimal surgery and consequently at higher risk for local
relapse may be suitable for postoperative radiotherapy, whereas
those receiving optimal surgery may be candidates to adjuvant
chemotherapy as they are considered at higher risk for metastatic
progression.
We then believe that our findings could help planning future trials
of postoperative management of gastric cancer patients, especially
now that new drugs are to be urgently tested in this setting.
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